Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma - Reassessment based on the revised Japanese national insurance reimbursement system

Annals of Nuclear Medicine

Volumn 17, Issue 8, 2003, Pages 649-655

  Abe, Katsumi ^a   Kosuda, Shigeru ^a   Kusano, Shoichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Cost benefit; ISF FDG; Lung cancer; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; JAPAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SIMULATION; WHOLE BODY SCINTISCANNING;

EID: 1042291322     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984970     Document Type: Article

References (17)

1. Torizuka K. Activity of national insurance application for FDG-PET examinations by the Japan Radioisotope Association, Medical and Pharmaceutical Committee [in Japanese]. ISOTOPE NEWS 2002; 577: 25-30.
2. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med 2002; 16: 263-271.
3. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma). KAKU IGAKU (Jpn J Nucl Med) 1998; 35: 395-404.
4. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary nodule (non-small-cell lung carcinoma) in Japan. Chest 2000; 117: 346-353.
5. Saegusa C, Adachi H, Imanaka K, Shimizu M, Hashimura T, Yonezawa K, et al. Clinical evaluation of silent brain metastasis in lung cancer patients [in Japanese]. Jpn J Lung Cancer 1990; 30: 521-526.
6. Mori K. The integrated basis of respiratory medicine [in Japanese]. Tokyo; Bunkodo, 1999; 507-566.
7. Habbema JD, Bossuyt PM, Dippel DW, Marshall S, Hilden J. Analyzing clinical decision analysis. Stat Med 1990; 9: 1229-1242.
8. Bury T, Dowlati A, Paulus P, Corhay JL, Hustinx R, Ghaye B, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997; 10: 2529-2534.
9. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212: 803-809.
10. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB. Staging lung cancer by whole-body PET-FDG imaging [Abstract]. J Nucl Med 1995; 36 (suppl): 95p.
11. Earnest IV F, Ryu JH, Miller GM, Luetmer PH, Forstrom LA, Burnett OL, et al. Suspected non-small cell lung cancer: Incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study. Radiology 1999; 211: 137-145.
12. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thoracic Surg 1999; 67: 790-797.
13. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39: 1016-1020.
14. 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20 (3B): 2189-2192.
15. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-1247.
16. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998; 66: 1876-1885.
17. Dietlein M, Weber K, Gandjour A, Maka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27: 1598-1609.